Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Right Down the Alli | Main | Real Life, Which Costs Real Money »

June 20, 2007

Bigger, Tougher, Longer? Or Not?

Email This Entry

Posted by Derek

Here's a question that was posed to me an an e-mail, which I thought I'd open up to everyone. Is the perception accurate that new clinical candidates (and new approved drugs) are getting more complex? And if so, are the processes used to make them getting longer and more complicated at the same rate?

I've seen the charts on the increasing molecular weight, etc., of candidates over the years, which is one surrogate for complexity. The relentless trend toward single enantiomers is probably a driver, too, so I'm certainly willing to credit the idea that the molecules are getting gradually woolier. What I'm wondering, though, is whether this is being reflected in the process work. Has anyone seen any statistics on "average number of chemical steps" or the like?

My guess is that it's been increasing, but more slowly. I think that modern synthetic methods are making up some of the difference, but I'd be interested in some actual, y'know, proof for this. Thoughts?

Comments (7) + TrackBacks (0) | Category: Drug Development | Drug Industry History


COMMENTS

1. TotallyMedicinal on June 20, 2007 9:37 AM writes...

Maybe it's a reflection on the increasing predominance of kinase research in pumping out candidates? Vieth's analysis in JMC (http://dx.doi.org/10.1021/jm0603825) indicates that the average kinase drug weighs 439, whereas the average ion channel drug only weighs 305. So more kinase candidates = more complex candidates in general.

Permalink to Comment

2. jose on June 20, 2007 4:32 PM writes...

From the title, I was thinking the topic of the post would be PDE5 inhibitors...

Permalink to Comment

3. totallyprocess on June 20, 2007 6:07 PM writes...

I don't think the historical data would indicate an overall increase in pharmaceutical target complexity over the last 20-30 years. Whether you measure step count, MW, # of chiral centers, or FTE per project, it does not trend towards higher complexity. Remember, you still have to contend with erythromycin (and other complex antibiotics, including the B-lactams, which are extremely difficult molecules to make), mevinolin (and other complex statins), crixivan (and other complex proteases). Some of these are semisynthetic; however, they still required multiple step manipulation of complicated, sensitive substrates with careful control and sophisticated analytical methods. I am not aware of a systematic, thorough investigation on this topic, but I have been involved in several discussions with people from various companies and I don't think that the data supports the assertion that "complexity", however one defines that, has significantly increased over the last 25-30 years. I would be interested in hearing alternate points of view.

Permalink to Comment

4. CET on June 21, 2007 1:04 AM writes...


Wasn't one of Lipinski's points that drug leads have gotten larger (among other things), but that the size of successful candidates hadn't changed much?

Permalink to Comment

5. Spiro on June 21, 2007 7:55 PM writes...

There is a good article by a pool of authors from process groups at GSK, AZ and Pfizer about "Analysis of the reactions used for the preparation of drug candidate molecules"
OrgBiomolChem 4 (2006), 2337 dx.doi.org/10.1039/b602413k

Excerpt : " The 128 syntheses contained 1039 chemical transformations, an average of 8.1 steps (GSK 7.9, AZ 8.2, Pfizer 8.1). The distribution of stages per compound is shown in Fig. 1."

This article is a bonanza of data, but it doesn't tell us how things have evolved over time.

There is also this other article "Survey of GMP Bulk Reactions Run in a Research Facility between 1985 and 2002" at Pfizer, Groton. Again a lot of data, with a comparison of the 1985-1996 and 1997-2002 periods, but the main point is missing :-(
Org. Process Res. Dev., 2005, 9, 253–258 dx.doi.org/10.1021/op050021j

Derek, if you are interested in a copy of these articles, e-mail me.

Permalink to Comment

6. Loon E. Toon on June 22, 2007 6:42 AM writes...

It seems to me that the clinical trials have, in some ways, both gotten simpler and gotten more complex.

Simpler, in that any drug candidate seems to be tested for just one possible indication, then later on tested for further, usually closely related, diseases. It almost seems as though drug companies want to do the bare minimum to be approved by the FDA, then show that it works for everything else.

More complex in that, post Vioxx (and even before) there is a concern about uncommon side effects and the statistical power to tease them out from the background. Following through for longer terms and using larger sample cohorts seems to be the norm, both of which are costly.

Permalink to Comment

7. Great Molecular Crapshoot on June 23, 2007 4:01 PM writes...

I guess one could answer the question by defining some elements of molecular complexity and analysing changes in these with time for launched drugs. Number of chiral centers is an obvious measure of complexity but one could also look at extent of substitution, unusual substitution patterns, rare rings and anything else that makes sense. There are (at least) two approaches to analysis. First you can look at how the properties of launched drugs vary with launch date. A potentially more informative tactic is it to track the molecular complexity elements through the development path. Both of these approaches have been used to look at size and lipophilicity measures and I recently reviewed some of this literature in The Crapshoot in ‘The Rule of 5: Riding the wake’ (there’s a rule of 5 label). I didn’t find much convincing evidence in the reviewed literature to support the view launched drugs are getting bigger.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All
Thiola, Retrophin, Martin Shkrell, Reddit, and More